Azosemide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585154

CAS#: 27589-33-9

Description: Azosemide is used in the treatment of oedematous states and hypertension.

Chemical Structure

img
Azosemide
CAS# 27589-33-9
Instruction

Theoretical Analysis

MedKoo Cat#: 585154
Name: Azosemide
CAS#: 27589-33-9
Chemical Formula: C12H11ClN6O2S2
Exact Mass: 370.01
Molecular Weight: 370.830
Elemental Analysis: C, 38.87; H, 2.99; Cl, 9.56; N, 22.66; O, 8.63; S, 17.29

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Azosemide; PLE 1053; SK-110

IUPAC/Chemical Name: Sulfanilamide, 2-chloro-5-(1H-tetrazol-5-yl)-N(sup 4)-2-thenyl-

InChi Key: HMEDEBAJARCKCT-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H11ClN6O2S2/c13-9-5-10(15-6-7-2-1-3-22-7)8(12-16-18-19-17-12)4-11(9)23(14,20)21/h1-5,15H,6H2,(H2,14,20,21)(H,16,17,18,19)

SMILES Code: NS(=O)(C1=CC(C2=NN=NN2)=C(NCC3=CC=CS3)C=C1Cl)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 370.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):5-13. doi: 10.1177/1074248413497257. Epub 2013 Nov 15. Review. PubMed PMID: 24243991.

2: Masuyama T, Tsujino T, Origasa H, Yamamoto K, Akasaka T, Hirano Y, Ohte N, Daimon T, Nakatani S, Ito H. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J. 2012;76(4):833-42. PubMed PMID: 22451450.

3: Suh OK, Kim SH, Lee MG. Pharmacokinetics and pharmacodynamics of azosemide. Biopharm Drug Dispos. 2003 Oct;24(7):275-97. Review. PubMed PMID: 14520682.

4: Fukui M, Tsujino T, Hirotani S, Ito H, Yamamoto K, Akasaka T, Hirano Y, Ohte N, Daimon T, Nakatani S, Kawabata M, Masuyama T. Changes in brain natriuretic peptide in chronic heart failure patients treated with long-acting versus short-acting loop diuretics: J-MELODIC subanalysis. Heart Vessels. 2017 Jul;32(7):865-871. doi: 10.1007/s00380-017-0945-z. Epub 2017 Jan 19. PubMed PMID: 28105515.

5: Kasama S, Toyama T, Kurabayashi M. Comparative effects of long and short-acting loop diuretics on mortality in patients with chronic heart failure. Int J Cardiol. 2017 Oct 1;244:242-244. doi: 10.1016/j.ijcard.2017.06.010. Epub 2017 Jun 15. PubMed PMID: 28645802.

6: Park KJ, Yoon WH, Kim SH, Shin WG, Lee MG. Pharmacokinetic and pharmacodynamic changes of azosemide after intravenous and oral administration of azosemide to uranyl nitrate-induced acute renal failure rats. Biopharm Drug Dispos. 1998 Apr;19(3):141-6. PubMed PMID: 9569995.

7: Matsuo Y, Kasama S, Toyama T, Funada R, Takama N, Koitabashi N, Ichikawa S, Suzuki Y, Matsumoto N, Sato Y, Kurabayashi M. Comparative effects of long-acting and short-acting loop diuretics on cardiac sympathetic nerve activity in patients with chronic heart failure. Open Heart. 2016 Feb 2;3(1):e000276. doi: 10.1136/openhrt-2015-000276. eCollection 2016. PubMed PMID: 26870386; PubMed Central PMCID: PMC4746525.

8: Toyoda S, Arikawa T, Inami S, Nishikawa R, Saito F, Watanabe R, Sakuma M, Kanaya T, Abe S, Inoue T. Patients With CONgestive Heart Failure Benefit From Long-Term Treatment Effects With Novel Treatment Using Azosemide Compared With Furosemide Derived From Existing Retrospective Study Data: CONTENTED. J Cardiovasc Pharmacol. 2019 Jun;73(6):365-372. doi: 10.1097/FJC.0000000000000669. PubMed PMID: 31162245.

9: Suzuki Y, Ito M, Komura T. [Pharmacological studies on diuretic action of azosemide [5-(4'-chloro-5'-sulfamoyl-2'-thenylamino)-phenyltetrazole], a new diuretic (2). Diuretic action of azosemide in HgCl2-induced acute renal failure in rats]. Nihon Yakurigaku Zasshi. 1982 Oct;80(4):289-98. Japanese. PubMed PMID: 6218035.

10: Asami M, Aoki J, Tanimoto S, Horiuchi Y, Watanabe M, Furui K, Yasuhara K, Sato T, Tanabe K, Hara K. Effects of Long-Acting Loop Diuretics in Heart Failure With Reduced Ejection Fraction Patients With Cardiac Resynchronization Therapy. Int Heart J. 2017 Apr 6;58(2):211-219. doi: 10.1536/ihj.16-290. Epub 2017 Mar 17. PubMed PMID: 28321027.

11: Hori Y, Katou A, Tsubaki M, Kanai K, Nakao R, Hoshi F, Itoh N, Higuchi S. Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemide in healthy dogs. Am J Vet Res. 2008 Dec;69(12):1664-9. doi: 10.2460/ajvr.69.12.1664. PubMed PMID: 19046016.

12: Kitada S, Kikuchi S, Tsujino T, Masuyama T, Ohte N; J-MELODIC study investigators. The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub-analysis of the J-MELODIC study. ESC Heart Fail. 2018 Feb;5(1):36-45. doi: 10.1002/ehf2.12206. Epub 2017 Sep 21. PubMed PMID: 28941144; PubMed Central PMCID: PMC5793961.

13: Hampel P, Römermann K, MacAulay N, Löscher W. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B. Sci Rep. 2018 Jun 29;8(1):9877. doi: 10.1038/s41598-018-27995-w. PubMed PMID: 29959396; PubMed Central PMCID: PMC6026185.

14: Miyata M, Sasaki T, Ikeda Y, Shinsato T, Kubozono T, Furusho Y, Kusumoto A, Hamasaki S, Tei C; COLD-CHF Investigators. Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF). J Cardiol. 2012 May;59(3):352-8. doi: 10.1016/j.jjcc.2011.12.007. Epub 2012 Feb 24. PubMed PMID: 22365947.

15: Kim EJ, Lee AK, Kim SH, Kim SG, Lee MG. Pharmacokinetics and pharmacodynamics of intravenous azosemide in mutant Nagase analbuminemic rats. Drug Metab Dispos. 2003 Feb;31(2):194-201. PubMed PMID: 12527700.

16: Han KS, Lee MG. Circadian changes in the pharmacokinetics and pharmacodynamics of azosemide in rats. J Pharm Pharmacol. 1998 Jul;50(7):767-74. PubMed PMID: 9720626.

17: Suzuki Y, Ito M, Komura T. [Pharmacological studies on the diuretic action of azosemide [5-(4'-chloro-5'-sulfamoyl-2'-thenylamino)-phenyltetrazole], a new diuretic (3). Effect of azosemide following pretreatment with SA-446, an angiotensin I converting enzyme inhibitor, or propranolol, a beta-adrenergic blocker, in HgCl2-induced acute renal failure in rats]. Nihon Yakurigaku Zasshi. 1982 Nov;80(5):395-404. Japanese. PubMed PMID: 6187650.

18: Choi KY, Kim YC, Lee MG. Mechanism of enhanced bioavailability and diuretic effect of azosemide by ascorbic acid in rats. Life Sci. 2006 Feb 2;78(10):1057-62. Epub 2005 Sep 8. PubMed PMID: 16153662.

19: Lee SH, Lee MG. Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokinet Biopharm. 1996 Dec;24(6):551-68. PubMed PMID: 9300350.

20: Lee SH, Lee MG. Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. Biopharm Drug Dispos. 1997 Jul;18(5):371-86. PubMed PMID: 9210976.